meRfi®-GM
Antibody-Drug-Conjugates (ADCs)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Most of the Antibody-Drug-Conjugates (ADCs), if not all, are immunotoxins but use whole antibodies and non-protein drugs
Although the recent FDA approval of six new antibody-drug conjugates (ADCs) is promising, attrition of ADCs during clinical development remains high.
The inherent complexity of Antibody-Drug-Conjugates (ADCs) is a double-edged sword that provides opportunities for perfecting therapeutic action while also increasing confounding factors in therapeutic failures.
Antibody-Drug-Conjugates (ADCs) design drives their …
References (Sources)
- Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
- Antibody–drug conjugates in cancer therapy
- Exploiting antibody biology for the treatment of cancer
- In Vitro Efficacy of Conjugates of Anti-GD4s Monoclonal Antibodies With Plant Toxin A-Chains
- Key metrics to expanding the pipeline of successful antibody–drug conjugates
- Optimizing antibody drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology
- Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy